Cardiff Oncology Inc (NASDAQ: CRDF) stock closed at $4.49 on 12/18/24 after a major decline of -16.1%. Moreover, unusually high trading volume at 153% of normal accompanied the decline. The stock has risen 18.8% during the last week but has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Cardiff Oncology has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Cardiff Oncology has a very low Appreciation Score of 7 and a very low Power Rating of 5, with the Lowest Value Trend Rating the result.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment